{"nctId":"NCT01705145","briefTitle":"Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation","startDateStruct":{"date":"2013-01"},"conditions":["Cystic Fibrosis"],"count":35,"armGroups":[{"label":"Ivacaftor","type":"EXPERIMENTAL","interventionNames":["Drug: Ivacaftor"]}],"interventions":[{"name":"Ivacaftor","otherNames":["Kalydeco","VX-770"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female with confirmed diagnosis of CF\n* Must have a CFTR gating mutation in at least 1 allele\n* Aged 2 through 5 years at screening and Day 1\n* Weight \\>= 8 kg at screening and Day 1\n* Hematology, serum chemistry, coagulation, and vital signs results at screening with no clinically significant abnormalities that would interfere with the study assessments, as judged by the investigator\n\nExclusion Criteria:\n\n* History of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant\n* An acute upper or lower respiratory infection, or pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks before Day 1\n* Abnormal liver function, at screening\n* History of solid organ or hematological transplantation\n* Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A within 2 weeks before Day 1\n* Participation in a clinical study involving administration of either an investigational or a marketed drug within 30 days or 5 terminal half-lives before screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"5 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs","description":"AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.\n\nRelated AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received and for overall participants.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"PRIMARY","title":"Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs","description":"AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. AE includes both serious and non-serious AE. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.\n\nRelated AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Plasma Concentration of Ivacaftor and Its Metabolites","description":"Plasma concentration was reported for ivacaftor and its metabolites (M1 and M6) up to 24 hours post-dose on Day 168 (Hour 0 \\[predose\\] on Day 1, 14, 56, 112, and 168余 2, 3, 6 hours post-dose on Day 14余 1 hour post-dose on Day 56余 4, 6 hours post-dose on Day 112余 24 hours post-dose on Day 168). Data was planned to be reported for overall participants in the period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"614","spread":"590"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"932","spread":"541"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1080","spread":"587"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1140","spread":"627"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"448","spread":"455"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"514","spread":"421"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"596","spread":"747"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1080","spread":"835"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1010","spread":"885"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"500","spread":"545"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":"372"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1580","spread":"1030"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1870","spread":"924"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2280","spread":"1140"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2670","spread":"1080"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1340","spread":"880"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1170","spread":"698"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1680","spread":"1360"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2450","spread":"1510"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2500","spread":"1520"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1460","spread":"1200"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"602","spread":"647"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1520","spread":"1130"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1430","spread":"989"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1630","spread":"1130"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2090","spread":"1350"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1510","spread":"1080"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1310","spread":"974"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1660","spread":"1130"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1810","spread":"1230"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2130","spread":"1380"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1520","spread":"1130"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"632","spread":"465"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Sweat Chloride at Week 24","description":"Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\\>=) 15 microliter was required for determination of sweat chloride. Data was reported as per the dose received and for overall participants.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.07","spread":"24.256"},{"groupId":"OG001","value":"-46.78","spread":"27.584"},{"groupId":"OG002","value":"-46.86","spread":"26.193"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Weight at Week 24","description":"Data was reported as per the dose received and for overall participants.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.418"},{"groupId":"OG001","value":"1.50","spread":"0.552"},{"groupId":"OG002","value":"1.36","spread":"0.561"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Stature at Week 24","description":"Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Data was reported as per the dose received and for overall participants.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"1.45"},{"groupId":"OG001","value":"3.5","spread":"0.93"},{"groupId":"OG002","value":"3.3","spread":"1.17"}]}]}]},{"type":"PRIMARY","title":"Part A: Plasma Concentration of Ivacaftor and Its Metabolites","description":"Plasma concentration was reported for ivacaftor and its metabolites (hydroxymethyl ivacaftor \\[M1\\] and ivacaftor carboxylate \\[M6\\]) up to 24 hours post-dose on Day 4 (Hour 0 \\[pre-dose\\] on Day 1 and Day 4; 2, 3, 6, 24 hours post-dose on Day 4). Data was planned to be reported for overall participants in the period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"396","spread":"337"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"726","spread":"284"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"957","spread":"283"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"542","spread":"241"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":"149"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1240","spread":"723"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1540","spread":"578"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2310","spread":"820"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1580","spread":"622"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"389","spread":"336"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1150","spread":"709"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1050","spread":"606"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1300","spread":"614"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1390","spread":"532"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"439","spread":"355"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24","description":"BMI = (Weight \\[in kg\\]) divided by (Stature \\[in meters\\])\\^2. Data was reported as per the dose received and for overall participants.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.332","spread":"0.5393"},{"groupId":"OG001","value":"0.314","spread":"0.5492"},{"groupId":"OG002","value":"0.319","spread":"0.5378"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":4},"commonTop":["Cough","Vomiting","Pyrexia","Nasal congestion","Rhinorrhoea"]}}}